Fresh analysis indicates that people who stop using popular GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass at a significantly accelerated pace than those who stop conventional lifestyle plans.
Findings released in a major health publication demonstrates that while overweight people often shed about a fifth of their total mass while on the medication, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"Individuals purchasing such medications should be informed of the risk of fast rebound weight gain when the medication is stopped," stated expert Dr. Susan Jebb.
Such speed of recovery means a reversion to original weight within about a year and a half.
Comparing Approaches
The study, which examined dozens of trials involving thousands of patients, contrasted the results of GLP-1 agonists with older methods.
The team point out that individuals who lose weight through diet and exercise typically experience a less rapid creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Rapid Regain
Doctors believe the mechanism of the drugs is key to understanding the amplified weight return.
These medications imitate a body's own chemical called GLP-1, which controls feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication results in appetite is no longer kept in check, making overeating far more likely."
A Lifelong Issue?
Medical guidelines advise the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Professionals say that, considering the high risk of weight regain, the therapy is often life-long.
This perspective is supported by pharmaceutical companies, who note that the results "underscore the persistent nature of excess weight," comparing it to managing conditions like hypertension.
User Testimonies
Users who have discontinued the jabs explain a intense return of appetite.
"I experienced a switch flipping and you're instantly ravenous," said a patient.
This challenge is worsened if patients have not developed lasting lifestyle or habit modifications during treatment.
Growing Use
Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Use is greater among women compared to men.
- The 40s and 50s age group shows the highest usage rates.
- Many access the medications through private healthcare rather than the NHS.
Ultimately, clinicians emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a standalone solution and lasting health benefits hinges on ongoing behavioural changes.
